AbX Biologics is Drug Discovery in United States that focus on developer business. Founded in 2019. They cover business area such as developer, immunization toolkit, antibody discovery service, high-throughput screening, hybridoma sequencing, antibody purification, affinity, therapeutic antibody discovery, reagent discovery, anti-idiotype antibody, account, your internal resource, early project design, communication, final product delivery.
2019
( 7 years old in 2026 )
Developer
-
480 Neponset Street
Suite 10B
Canton, MA 02021
United States
Private
developerimmunization toolkitantibody discovery servicehigh-throughput screeninghybridoma sequencingantibody purificationaffinitytherapeutic antibody discoveryreagent discoveryanti-idiotype antibodyaccountyour internal resourceearly project designcommunicationfinal product delivery
* We use standard office opening hours in near AbX Biologics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
AbX Biologics is Drug Discovery business from United States that founded in 2019 (7 years old in 2026), AbX Biologics business is focusing on Developer.
AbX Biologics headquarter office and corporate office address is located in 480 Neponset Street Suite 10B Canton, MA 02021 United States.
AbX Biologics was founded in United States.
In 2026, AbX Biologics is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with AbX Biologics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
